IGC Pharma reports Q3 EPS (2c) vs. (9c) last year

Reports Q3 revenue $257,000 vs. $204,000 last year. “The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer’s,” said Mr. Ram Mukunda, CEO. “We are also planning to explore IGC-AD1 as an Alzheimer’s disease-modifying therapy, aimed at reducing plaques and tangles in the brain, which positions IGC-AD1 in a significantly broader market. Our AI-driven research also gained recognition from the NIH through the PREPARE Challenge, reinforcing our leadership in Alzheimer’s innovation. As we continue executing our strategy across Alzheimer’s and metabolic disorders, we remain committed to delivering transformative therapies and driving long-term value for shareholders.”